Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease

被引：0
|
作者：
Schmidt, Andrew Lachlan
Anton, Angelyn
Wong, Shirley S.
Azad, Arun
Kwan, Edmond Michael
Spain, Lavinia Anne
Torres, Javier
Muthusamy, Arunbalaji
Parente, Phillip
Parnis, Francis
Goh, Jeffrey C.
Joshua, Anthony M.
Pook, David William
Gibbs, Peter
Tran, Ben
Weickhardt, Andrew James
机构：
[1] Dept Med Oncol, Brisbane, Qld, Australia
[2] Peter MacCallum Canc Ctr, Melbourne, Australia
[3] Western Hosp, Brunswick, ME, Australia
[4] Monash Hlth, Dept Med Oncol, Melbourne, Australia
[5] Monash Univ, Melbourne, Australia
[6] Goulburn Valley Hlth, Shepparton, Australia
[7] Austin Hlth, Melbourne, Vic, Australia
[8] Eastern Hlth, Melbourne, Vic, Australia
[9] Monash Univ, Eastern Hlth Clin Sch, Melbourne, Vic, Australia
[10] Adelaide Canc Ctr, Adelaide, SA, Australia
[11] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
[12] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[13] Monash Hlth, Dept Med Oncol, Melbourne, Vic, Australia
[14] Royal Melbourne Hosp, Melbourne, Vic, Australia
[15] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[16] Austin Hlth, Olivia Newton John Canc Wellness & Res Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
78
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Exosomal microRNA as prognostic biomarkers in metastatic castrate-resistant prostate cancer (mCRPC).
    Kohli, Manish
    Huang, Xiaoyi
    Yuan, Tiezheng
    Sun, Zhifu
    Costello, Brian Addis
    Quevedo, Fernando
    Tan, Winston
    Nandy, Debashis
    Longenbach, Sherri
    Wang, Liang
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [22] Treatment sequencing in metastatic castrate-resistant prostate cancer
    Sartor, Oliver
    Gillessen, Silke
    ASIAN JOURNAL OF ANDROLOGY, 2014, 16 (03) : 426 - 431
  • [23] Impact of comorbidity on outcome in men with metastatic castrate-resistant prostate cancer (mCRPC)
    Zist, A.
    Amir, E.
    Ocana, A.
    Seruga, B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S703 - S703
  • [24] Pembrolizumab (pembro) in heavily pretreated metastatic castrate-resistant prostate cancer (mCRPC).
    Moses, Marcus Marie
    Ledet, Elisa
    Manogue, Charlotte
    Lewis, Brian E.
    Barata, Pedro C.
    Sartor, A. Oliver
    Layton, Jodi Lyn
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [25] Metastatic castrate-resistant prostate cancer
    Schellhammer, Paul
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (01) : 51 - 52
  • [26] Characteristics and outcome of octogenarian versus young patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) treated with ketoconazole.
    Sinibaldi, Victoria J.
    Dadon-Nachum, Michal
    Gottfried, Maya
    Maimon, Natalie
    Dovrish, Zamir
    Peer, Avivit
    Neumann, Avivit
    Sella, Avishay
    Kovel, Svetlana
    Carducci, Michael Anthony
    Eisenberger, Mario A.
    Kejzman, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [27] Intermittent Docetaxel Chemotherapy in Patients With Castrate-resistant Prostate Cancer
    Mountzios, Ioannis
    Bournakis, Evangelos
    Efstathiou, Eleni
    Varkaris, Andreas
    Wen, Sijin
    Chrisofos, Michael
    Deliveliotis, Charalambos
    Alamanis, Christos
    Anastasiou, Ioannis
    Constantinides, Constantine
    Karadimou, Alexandra
    Tsiatas, Marinos
    Papadimitriou, Christos
    Bamias, Aristotelis
    Dimopoulos, Meletios A.
    UROLOGY, 2011, 77 (03) : 682 - 687
  • [28] Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer
    Davies, Rhian Sian
    Smith, Christian
    Lester, Jason Francis
    ANTICANCER RESEARCH, 2016, 36 (04) : 1799 - 1803
  • [29] Docetaxel chemotherapy for Chinese patients with castrate-resistant prostate cancer
    Cheung, F. Y.
    Leung, K. C.
    Ngan, Roger K. C.
    HONG KONG MEDICAL JOURNAL, 2013, 19 (03) : 237 - 241
  • [30] Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer
    Wissing, Michel D.
    van Diest, Paul J.
    van der Wall, Elsken
    Gelderblom, Hans
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (05) : 635 - 661
12345